Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in pediatric solid tumors with KIT or PDGFRA mutations
NCT04773782Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Feb 2022
- Primary completion
- Nov 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
A Phase 2 trial of avapritinib in solid tumor, central nervous system tumor, diffuse midline glioma (DMG), sponsored by Blueprint Medicines. Started Feb 2022; status: completed.
02
Drugs
avapritinib
03
Conditions
solid tumorcentral nervous system tumordiffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04773782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773782.